British speciality chemicals major Croda International has unveiled a new supply partnership with German manufacturer Amino GmbH, a move aimed at shoring up worldwide access to the high-purity amino acids crucial for pharmaceutical formulation and modern biomanufacturing.

 

Amino acids — the molecular building blocks of proteins — play an increasingly vital role in the drug industry, serving both as excipients in biologic formulations and as essential components in the production of monoclonal antibodies and other biological therapies.

 

Announcing the deal, Thomas Riermeier, President of Life Sciences, said: “Our collaboration marks an exciting step forward in expanding the high-quality ingredients available to biopharma developers. By working together, we’re helping customers increase the efficiency of their processes and advance the therapies that will shape the future of patient care.”

 

The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities, positioning the companies to deliver more innovative and sustainable ingredient solutions to the biopharma sector.

 

Katie Dec, Global Business Director of Croda Pharma Insights, said the alliance directly supports Croda’s long-term strategy. "This partnership reflects Croda’s strategy, to strengthen our ability to support customers in the fast-evolving biopharma landscape,” she said. "Amino’s strong reputation and expertise make them an ideal partner as we continue to deliver high-quality, reliable materials needed to bring new therapies to market.” 

 

Dec added that Croda will launch its new BioXPro high-purity histidine and arginine products in January, noting, “These products will provide the purity, consistency, and batch-to-batch reproducibility that our customers value.”

 

Amino hailed the collaboration as a major step in its biopharmaceutical growth plans. “The partnership with Croda is both a milestone and a catalyst for Amino’s ambitions in biopharmaceuticals. The combination of Croda’s market reach and our high-purity amino acid production expertise forms a partnership dedicated to meeting specific customer demands,” said Managing Director Lutz Thomas.

 

The agreement strengthens Croda’s push to supply top-tier ingredients for pharmaceutical formulation and biomanufacturing, following recent launches including Virodex for viral inactivation and cell lysis, and Super Refined Poloxamer 188 for shear protection in cell culture media.